ODN 1668
目录号 : GC68294ODN 1668是一种含有CpG基序的合成寡脱氧核苷酸（ODN），是Toll样受体9（TLR9）的激动剂。
Cas No.:1186063-66-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
ODN 1668 is a synthetic oligodeoxynucleotide (ODN) containing CpG motifs and acts as an agonist of Toll-like receptor 9 (TLR9)[1]. CpG ODN 1668 has been reported to enhance the antibacterial effects of Rhamdia quelen against Aeromonas hydrophila infection[2].
In vitro, ODN 1668 (2μg/ml; 12h) significantly enhances the antibacterial immunity of head kidney lymphocytes (HKLs). In addition, ODN 1668 (0, 0.175, 0.25, 0.5, 1, 2, 4, 8, 16 and 32μg/ml; 12h) also promotes the cell proliferation and immune gene expression of HKLs, and strengthens the phagocytic activity of head kidney macrophages[3]. Stimulation of macrophages with ODN 1668 (1μM; 6h) increases the production of the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1Ra) in a Toll-like receptor 9 (TLR9) and MyD88-dependent manner, thereby enhancing macrophage migration and promoting macrophage proliferation[4].
In vivo, ODN 1668 (15μg/fish; 24h; i.m.) significantly enhances the antibacterial immune response in humpback grouper[3]. Administration of a Toll-like receptor 9 (TLR9) agonist ODN 1668 (10μg/kg/weekly; 8 weeks; i.v.) to apolipoprotein E-deficient (ApoE-/-) mice resulted in a reduction of atherosclerotic lesion severity[5].
References:
[1] Damm J, Wiegand F, Harden LM, Wenisch S, Gerstberger R, Rummel C, Roth J. Intraperitoneal and subcutaneous injections of the TLR9 agonist ODN 1668 in rats: brain inflammatory responses are related to peripheral IL-6 rather than interferons. J Neuroimmunol. 2014 Dec 15;277(1-2):105-17.
[2] Canova, Raíssa, Kirsten K S , Lucas D F S ,et al.Oligodeoxynucleotides CpGs increase silver catfish (Rhamdia quelen) resistance to Aeromonas hydrophila challenge[J].Aquaculture, 2017, 473:278-282.
[3] Chen X, Zhang P, Li P, Wang G, Li J, Wu Y, Cao Z, Zhou Y, Sun Y. CpG ODN 1668 as TLR9 agonist mediates humpback grouper (Cromileptes altivelis) antibacterial immune responses. Fish Shellfish Immunol. 2023 Jul;138:108839.
[4] Chen TA, Liao CC, Cheng YC, Chen YP, Hsu YF, Liang CM, Liang SM. Stimulation of Proliferation and Migration of Mouse Macrophages by Type B CpG-ODNs Is F-Spondin and IL-1Ra Dependent. PLoS One. 2015 Jun 4;10(6):e0128926.
[5] Koulis C, Chen YC, Hausding C, Ahrens I, Kyaw TS, Tay C, Allen T, Jandeleit-Dahm K, Sweet MJ, Akira S, Bobik A, Peter K, Agrotis A. Protective role for Toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):516-25.
ODN 1668是一种含有CpG基序的合成寡脱氧核苷酸（ODN），是Toll样受体9（TLR9）的激动剂[1]。CpG ODN 1668已被报道能够增强银尾鲶（Rhamdia quelen）抵抗嗜水气单胞菌（Aeromonas hydrophila）感染的抗菌效果[2]。
在体外实验中，ODN 1668（2μg/ml; 12h）显著增强了头部肾脏淋巴细胞（HKLs）的抗菌免疫能力[3]。此外，ODN 1668（0, 0.175, 0.25, 0.5, 1, 2, 4, 8, 16和32μg/ml; 12h）还促进了头部肾脏淋巴细胞的细胞增殖和免疫基因表达，并增强了头部肾脏巨噬细胞的吞噬活性[3]。用ODN 1668（1μM; 6h）刺激巨噬细胞，能够通过依赖Toll样受体9（TLR9）和髓样分化因子88（MyD88）的方式，增加抗炎细胞因子白细胞介素1受体拮抗剂（IL-1Ra）的产生，从而增强巨噬细胞的迁移能力并促进其增殖[4]。
在体内实验中，ODN 1668（15μg/尾; 24h; 肌肉注射）显著增强了斜带石斑鱼的抗菌免疫反应[3]。向载脂蛋白E缺陷（ApoE-/-）小鼠给予Toll样受体9（TLR9）激动剂ODN 1668（10μg/kg/每周一次; 8周; 静脉注射）后，动脉粥样硬化病变的严重程度有所减轻[5]。
| Cell experiment [1]: | |
Cell lines | head kidney lymphocytes (HKLs) |
Preparation Method | 100μl HKLs (1×108 cells/ml) were added into 96-well plates and cultured for 1h. Cells were stimulated by adding 2μl ODN 1668 (final concentration of 2μg/ml) or PBS (control group). After 12h of stimulation, 10μl 1 × 106 CFU/ml E. tarda was added and incubated for 2, 6, and 12h at 26°C. After that, the cells were lysed with 50μl of 1% Triton X-100 for 3min, and the cell lysate was serially diluted and plated in triplicate on LB agar plates. The number of bacterial colonies was determined on the basis of plate count. To further analyse whether ODN 1668 has bactericidal ability, 2μl ODN 1668 (final concentration of 2μg/ml) or PBS (control group) were incubated with 100μl 1×105 CFU/ml E. tarda for 6h at 28°C in vitro. The number of bacterial colonies was determined on the basis of plate count. |
Reaction Conditions | 2μg/ml; 12h |
Applications | ODN 1668 (2μg/ml; 12h) significantly enhances the antibacterial immunity of head kidney lymphocytes (HKLs). |
| Animal experiment [2]: | |
Animal models | C57Bl/6, TLR9−/−:ApoE−/− double knockout (DKO) male mice |
Preparation Method | Eight-week-old ApoE−/− mice were fed a high-fat diet containing 21% butterfat and 0.15% cholesterol and were administered either the type B CpG oligodeoxynucleotide TLR9 agonist ODN 1668 (10μg/kg/weekly; i.v.) or vehicle (PBS) for a total of 8 weeks. Subsequently, the size of atherosclerotic lesions was determined by Oil-Red O staining. |
Dosage form | 10μg/kg/weekly; 8 weeks; i.v. |
Applications | Administration of a Toll-like receptor 9 (TLR9) agonist ODN 1668 (10μg/kg/weekly; i.v.) to apolipoprotein E-deficient (ApoE-/-) mice resulted in a reduction of atherosclerotic lesion severity. |
References: | |
| Cas No. | 1186063-66-0 | SDF | Download SDF |
| 分子式 | 分子量 | ||
| 溶解度 | H2O : ≥ 20 mg/mL (3.14 mM) | 储存条件 | Store at -20°C, away from moisture |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet